http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Alpha-synuclein quantitative seed amplification assay predicts conversion to dementia.
Bräuer, S. (First author)DZNE* ; Sondermann, V.DZNE* ; Schniewind, I.DZNE* ; Hähnel, T.DZNE* ; Dinter, E.DZNE* ; Kleineidam, L.DZNE* ; Stark, M.DZNE* ; Schmid, M.DZNE* ; Sodenkamp, S.DZNE* ; Laske, C.DZNE* ; Spruth, E.DZNE* ; Priller, J.DZNE* ; Janowitz, D.Extern* ; Bürger, K.DZNE* ; Kilimann, I.DZNE* ; Teipel, S.DZNE* ; Storch, A.DZNE* ; Hansen, N. ; Wiltfang, J.DZNE* ; Glanz, W.DZNE* ; Düzel, E.DZNE* ; Preis, L.Extern* ; Peters, O.DZNE* ; Hellmann-Regen, J.DZNE* ; Wagner, M.DZNE* ; Bernhardt, A. M.Extern* ; Levin, J.DZNE* ; Petzold, G.DZNE* ; Kronmüller, M.DZNE* ; Gamez, A.DZNE* ; Spottke, A.DZNE* ; Brosseron, F.DZNE* ; Rostamzadeh, A. ; Jessen, F.DZNE* ; Hermann, A.DZNE* ; Fliessbach, K.DZNE* ; Schneider, A.DZNE* ; Falkenburger, B. H. (Last author)DZNE*
2026
Wiley
Hoboken, NJ
This record in other databases:
Please use a persistent id in citations: doi:10.1002/alz.71167
Abstract: The alpha-synuclein seed amplification assay (SAA) has shown excellent performance in the detection of Lewy body pathology in cerebrospinal fluid (CSF). Lewy body pathology is prognostically relevant in patients at risk for dementia. Current assays only provide binary results, so there is a need to quantify the extent of pathology in living patients.In addition to the 'standard' SAA, we developed a quantitative SAA (qnSAA) and measured 432 CSF samples (216 baseline-follow-up pairs).qnSAA results correlated with cognitive performance. Seventy-five percent of participants with fast qnSAA kinetics converted to dementia in the observed interval. Overall, participants with fast qnSAA kinetics accounted for 27.3% of dementia converters in the entire cohort.Findings demonstrate promising properties of qnSAA measurements in a cohort of patients at risk for dementia. qnSAA results showed improved prognostic relevance and have potential to measure target engagement of therapies against Lewy body pathology.
Keyword(s): Humans (MeSH) ; alpha-Synuclein: cerebrospinal fluid (MeSH) ; Male (MeSH) ; Female (MeSH) ; Dementia: cerebrospinal fluid (MeSH) ; Dementia: diagnosis (MeSH) ; Aged (MeSH) ; Disease Progression (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Aged, 80 and over (MeSH) ; Lewy Body Disease: cerebrospinal fluid (MeSH) ; Prognosis (MeSH) ; Cohort Studies (MeSH) ; Alzheimer´s disease ; Lewy body ; alpha‐synuclein ; dementia ; real‐time quaking‐induced conversion ; seed amplification assay ; alpha-Synuclein ; Biomarkers
Contributing Institute(s):
- Translational Parkinson Research (AG Falkenburger)
- Neuropsychology (AG Wagner)
- Mathematics, statistics and informatics methods for support of population studies and clinical research (AG Schmid Bonn)
- Core ICRU (ICRU)
- Parkinson Genetics (AG Gasser)
- Translational Neuropsychiatry (AG Priller)
- Clinical Research (Munich) (Clinical Research (Munich))
- Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
- Non-Motor Symptoms in Parkinson's disease (AG Storch)
- Molecular biomarkers for predictive diagnostics of neurodegenerative diseases (AG Wiltfang)
- Clinical Neurophysiology and Memory (AG Düzel)
- Biomarker-Assisted Early Detection of Dementias (AG Peters)
- Interdisciplinary Dementia Research (AG Endres)
- Clinical Neurodegeneration (AG Levin)
- Vascular Neurology (AG Petzold)
- Clinical Research Platform (CRP) (AG Spottke)
- Neuroinflammation, Biomarker (AG Heneka)
- Clinical Alzheimer’s Disease Research (AG Jessen)
- Translational Neurodegeneration (AG Hermann)
- Patient Studies (Bonn) (Patient Studies (Bonn))
- Translational Dementia Research (Bonn) (AG Schneider)
Research Program(s):
- 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection